ABK Biomedical Inc.
ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. ABK Biomedical inc. products are considered investigational products and are NOT FDA approved for use. Y90 radioembolization. Founded in 2012, we are focused on researching, developing, and commercializing breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors.
We also maintain a future vision of expanded human-body applications for our radioembolization and bland embolotherapy therapies for continuous improvement of patient outcomes.Our History
To support this advancing technology, we assembled an expert, multidisciplinary senior management team and invested in expanded R&D and manufacturing facilities. ABK Biomedical raised $30M USD in Series B funding in 2019, the largest medical venture capital raise in Atlantic Canada.
ABK Biomedical is dedicated to providing a stimulating work environment that offers growth opportunities, employee benefits, and exciting career challenges.
We accomplish our mandate through multi-disciplinary teams experienced in engineering, material science, oncology, medical science, regulatory, finance, business development, sales, marketing, and clinical study coordination.